Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 1,359 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: FAST alone Clear all
Completed Early Phase 1 Interventional

Optimizing Acquisition Parameters and Interpretive Methods of FDG-PET/CT With Rb-82

NCT03048097
View directory record Official record
Conditions
Sarcoidosis
Interventions
Fluorodeoxyglucose, Rubidium, FDG-PET/CT with Rb82 Myocardial Perfusion Imaging
Drug · Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 26, 2019 · Synced Oct 24, 2026, 5:37 PM EDT
Completed Not applicable Interventional

Default Bulk Ordering and Text Messaging to Enhance Outreach for Lipid Screening (Missing Lipids)

NCT05724615
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Outreach + Bulk ordering, Outreach + Bulk ordering + Text Based Reminders and Scheduling assistance
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
20 Years to 75 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 24, 2026, 5:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Midazolam in Healthy Subjects

NCT02147808
View directory record Official record
Conditions
Drug Interactions
Interventions
Telotristat etiprate, Midazolam
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Oct 24, 2026, 5:37 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of the OsciPulse Rapid Cycling Compression Device Effects on Venous Blood Flow

NCT05087108
View directory record Official record
Conditions
Venous Thromboses, Venous Stasis
Interventions
OsciPulse system, Reference Therapy 1, Refence Therapy 2
Device
Lead sponsor
OsciFlex LLC
Industry
Eligibility
40 Years to 90 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 9, 2023 · Synced Oct 24, 2026, 5:37 PM EDT
Completed Phase 1 Interventional

Pharmacokinetic Study of CYCLOSET ® 0.8 mg Tablets in Children and Adolescent Type 2 Diabetes Mellitus Subjects

NCT02078440
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Bromocriptine mesylate
Drug
Lead sponsor
VeroScience
Industry
Eligibility
10 Years to 17 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Phoenix, Arizona • New Haven, Connecticut • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2016 · Synced Oct 24, 2026, 5:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Fosinopril Sodium / Hydrochlorothiazide 20/ 12.5 mg Tablets Under Fed Conditions

NCT00778713
View directory record Official record
Conditions
Healthy
Interventions
Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 23, 2008 · Synced Oct 24, 2026, 5:37 PM EDT
Recruiting Not applicable Interventional

7-Days Water-Only Fasting or Ketone Supplementation Trial in Prostate Cancer

NCT06826924
View directory record Official record
Conditions
Prostate Cancer, Prostate Cancer Metastatic
Interventions
Fasting, Ketone Supplementation
Behavioral · Dietary Supplement
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 24, 2026, 5:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants

NCT06264440
View directory record Official record
Conditions
Healthy Volunteer
Interventions
BIIB122, Rabeprazole
Drug
Lead sponsor
Biogen
Industry
Eligibility
30 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2024 · Synced Oct 24, 2026, 5:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Testing Non-Nutrition Menu Labels on Food Selections

NCT07536126
View directory record Official record
Conditions
Food Selection
Interventions
Control (QR) Labels, Low Environmental Harm Labels, High Environmental Harm Labels, Environmental Harm Traffic Light Labels, Environmental Grade Labels
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
7,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 24, 2026, 5:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ziresovir in Healthy Subjects

NCT04788017
View directory record Official record
Conditions
Healthy Subjects
Interventions
Ziresovir, Placebo
Drug · Other
Lead sponsor
Shanghai Ark Biopharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Oct 24, 2026, 5:37 PM EDT
Completed Phase 3 Interventional Results available

Second Line Induction Therapy and Healthy Diet for Patients With Ulcerative Colitis

NCT04505410
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
A plant based high fiber diet that mimics fasting ("FMD") plus advanced therapy, Advanced therapy only without dietary intervention
Other · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 24, 2026, 5:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Proof of Concept (POC) Study of the Soliton Rapid Acoustic (RAP) for the Treatment of Cellulite

NCT03981198
View directory record Official record
Conditions
Cellulite
Interventions
Soliton Rapid Acoustic Pulse (RAP)
Device
Lead sponsor
Soliton
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 24, 2026, 5:37 PM EDT
Completed Phase 2 Interventional Results available

BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma

NCT00117637
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Sorafenib (Nexavar, BAY43-9006), Interferon
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
9
States / cities
Sacramento, California • Aurora, Colorado • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2014 · Synced Oct 24, 2026, 5:37 PM EDT
Recruiting Phase 4 Interventional

REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE

NCT07476339
View directory record Official record
Conditions
HIV -1 Infection, HIV (Human Immunodeficiency Virus), HIV, HIV 1 Infection
Interventions
Bictegravir, emtricitabine, and tenofovir alafenamide
Drug
Lead sponsor
CAN Community Health
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Clearwater, Florida • Ft. Pierce, Florida • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 24, 2026, 5:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Investigation Of Absorption And Pharmacokinetics Of A Single Dose Of Controlled Release Pregabalin Tablet Administered Fasted In The Evening or Immediately Following A 600-750 Calorie Evening Meal As Compared To Single Dose Of Immediate Release Pregabalin Capsule In Healthy Volunteers

NCT01321671
View directory record Official record
Conditions
Healthy
Interventions
Pregabalin controlled release, 330 mg, 600- 750 calorie, Pregabalin controlled release, 330 mg, fasted, Pregabalin immediate release, 300 mg
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 24, 2026, 5:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Famciclovir 500 mg Tablets Under Non-Fasting Conditions

NCT00834444
View directory record Official record
Conditions
Healthy
Interventions
Famciclovir 500 mg Tablets, Famvir® 500 mg Tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 24, 2026, 5:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study for Multiple Tablet Forms of The Study Medicine (PF-07220060) in Healthy Adults

NCT05923411
View directory record Official record
Conditions
Healthy Participants
Interventions
Single dose of PF-07220060 as first Tablet Formulation, Single dose of PF-07220060 as second Tablet Formulation, Single dose of PF-07220060 as a Tablet Formulation, Single dose of PF-07220060 as a Tablet formulation under Rabeprazole administration, Single dose of PF-07220060 as third tablet formulation
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 24, 2026, 5:37 PM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Comparing Facial Aging Between Identical Twins With 3D Imaging

NCT07760532
View directory record Official record
Conditions
Facial Skin Aging, Facial Volume Loss, Wrinkle Appearance
Interventions
GLP-1 Receptor Agonists
Drug
Lead sponsor
Ponsky Facial Aesthetics And Plastic Surgery, Llc
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Beachwood, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 24, 2026, 5:37 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of Oral MG001

NCT07204171
View directory record Official record
Conditions
Safety and Tolerability in Healthy Subjects
Interventions
mitragynine, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 24, 2026, 5:37 PM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability, and Pharmacokinetics of KBP-5074 Following Oral Administration in Chronic Kidney Disease

NCT02837237
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
KBP-5074
Drug
Lead sponsor
KBP Biosciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 24, 2026, 5:37 PM EDT
Completed Phase 4 Interventional Results available

Ketamine For Suicidal Ideation

NCT01507181
View directory record Official record
Conditions
Suicidal Ideation
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
James Murrough
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 24, 2026, 5:37 PM EDT
Completed Not applicable Interventional

The Use of Penicillin Allergy Clinical Decision Rule to Enable Direct Oral Penicillin Challenge

NCT04454229
View directory record Official record
Conditions
Hypersensitivity, Immediate, Hypersensitivity, Delayed, Hypersensitivity Response
Interventions
Direct oral penicillin challenge, Standard of care
Other
Lead sponsor
Austin Health
Government
Eligibility
18 Years and older
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Durham, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Oct 24, 2026, 5:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Protecting Native Families From COVID-19

NCT04765475
View directory record Official record
Conditions
COVID-19
Interventions
Motivational Interviewing, COVID-19 Symptom Monitoring System, Motivational Interviewing and COVID-19 Symptom Monitoring System, Supportive Services
Behavioral · Other
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Whiteriver, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Oct 24, 2026, 5:37 PM EDT
Active, not recruiting Phase 2 Interventional Results available

TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies

NCT03849651
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), NK-Cell Leukemia, Hodgkin Lymphoma, Non Hodgkin Lymphoma (NHL), Juvenile Myelomonocytic Leukemia (JMML), Chronic Myeloid Leukemia (CML)
Interventions
Cyclophosphamide, Fludarabine, Thiotepa, Melphalan, G-csf, Mesna, CliniMACS, ATG (rabbit), Blinatumomab, TCRα/β+, CD19+, CD45RA-depleted DLI
Drug · Biological · Device
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 24, 2026, 5:37 PM EDT